Pharmacogenetics of antipsychotic therapy: Pivotal research issues and the prospects for clinical implementation

Dialogues in Clinical Neuroscience

Volumn 8, Issue 1, 2006, Pages 85-94

  Lerer, Bernard ^a   Segman, Ronnen H ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Atypical antipsychotic; Pharmacogenetics; Tardive dyskinesia; Typical antipsychotic

Indexed keywords

NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; DEMOGRAPHY; DNA POLYMORPHISM; DRUG EFFICACY; GENE INTERACTION; GENETIC VARIABILITY; GROUPS BY AGE; HAPLOTYPE; HEREDITY; HUMAN; PHARMACOGENETICS; PHENOTYPE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PHARMACOGENETICS; PSYCHOTIC DISORDERS; SEX FACTORS; VARIATION (GENETICS);

EID: 33646152737     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lerer B, ed. Pharmacogenetics of Psychotropic Drugs. Cambridge, UK: Cambridge University Press; 2002.
2. Pickar D, Rubinow K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci. 2001;22:75-83.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
4. Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882-1888.
5. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 2000;25:197-220.
6. 3 receptor gene ser9gly polymorphism. Neuropsychopharmacology. 2001;27:109-119.
7. Inada T, Dobashi I, Sugita T, et al. Search for a susceptibility locus to tardive dyskinesia. Hum Psychopharmacol. 1997;12:35-39.
8. 3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology. 2001;44:95-98.
9. 3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm. 2001;108:671-677.
10. Lerer B, Segman RH, Tan E-C, et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol. 2005;8:411-425.
11. 2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry. 2001;6:579-585.
12. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet. 1999;65:220-228.
13. 3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiatry. 2002;7:137-139.
14. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry. 2001;6:225-229.
15. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Gen. 2002;11:2517-2530.
16. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia; additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology. 2000;152:408-413.
17. 3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry. 2002;51:261-263.
18. Feigelson IS, Shames IS, Pike MC, Coerzec GA, Stanozyk PZ, Henderson BE. Cytochrome P450c17alpha gene polymorphism is associated with elevated estrogen and progesterone concentrations. Cancer Res. 1998;S8:585-587.
19. Basile VS, Ozdemir V, Masellis M, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry. 2001;6:230-234.
20. Hori H, Ohmori O, Shinkai T. Manganese superoxide dismutase dene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology. 2000;23:170-177.
21. Zhang ZJ, Zhang XB, Hou G, Sha WW, Reynolds GP. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatry Res. 2002;36:317-324.
22. 3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatr Genet. 2003;13:187-192.